The Bull Rankings scorecard — our quality-growth score is 83.2 / 100, built from three pillars each graded 0–100 against sector peers: Quality 85, Growth 88, Value 77. At today's price, our reverse-DCF read says the market is implicitly betting on about 3% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
EXLS is a high-quality growth engine that the market is undervaluing. The Bull Rankings model hands it an 83.2/100 quality-growth score, with Growth as the strongest pillar (88) and Value the weakest (77). That split tells us the business is delivering the earnings expansion the model rewards, but the price still lags the intrinsic story. As of the quarter ended 2026-03-31, the stock trades at $34.56, a P/E of 21.9—well below the 30-plus multiples that peers with similar growth command. Meanwhile, revenue is climbing 13.4% YoY, profit margins sit at 11.7%, and ROE is a blistering 32.3%. Those three numbers alone justify a growth-oriented rating, and the model’s “Buying back stock” signal adds a tangible catalyst that can lift the weak Value pillar toward parity.
What the business actually is
ExlService is a data- and AI-focused services firm that stitches analytics into the core operations of insurers, healthcare and life-science companies, banks, capital-market participants, and a host of diversified industries. Its playbook spans claims management, premium and benefit administration, agency and account reconciliation, actuarial and risk analytics, policy research, digital marketing, underwriting support, new-business acquisition, policy servicing, audit, surveys, billing and collection. The Insurance segment is the cash-cow, feeding the bulk of recurring revenue, while the Healthcare & Life Sciences arm is the fastest-growing line-item, buoyed by AI-driven clinical data processing and regulatory-compliance analytics. International Growth Markets provide a runway for the same digital-operations playbook in Europe and beyond.
Why it can keep compounding
The numbers betray a moat built on data depth and AI integration that rivals can’t duplicate overnight. A profit margin of 11.7% on a business that is essentially a high-margin knowledge service is hard to erode; the cost structure is dominated by skilled talent and proprietary models, not commodity hardware. Coupled with a ROE of 32.3%, the firm is turning equity into earnings at a rate that outpaces most IT-services peers, confirming the model’s “Durable high returns” signal. The AI-enabled analytics stack creates switching costs: insurers that embed EXLS’s claims-automation platform into their legacy systems face prohibitive migration costs, locking in multi-year contracts. The recent acquisition of iMerit, highlighted by simplywall.st, deepens the data-labeling capability, sharpening the AI advantage and feeding the growth engine in both Insurance and Healthcare.
The valuation question
At $34.56 the market assigns a P/E of 21.9 and a PEG of 1.03, implying that earnings are expected to grow roughly in line with the price-to-earnings multiple. Our reverse-DCF shows the current price embeds ≈3% annual free-cash-flow growth for the next decade. That is starkly lower than the 13.4% revenue growth recorded YoY. In other words, the market is discounting the growth story—perhaps because the Value pillar (77) flags a modest price-to-sales or free-cash-flow yield relative to peers. The debt-to-equity of 0.57 keeps the balance sheet flexible, but the low implied FCF growth suggests investors are skeptical that the AI-driven revenue surge can translate into sustained cash generation. If the firm can sustain its current margin and translate top-line expansion into free cash at the historical rate, the valuation gap widens, making the stock a clear upside case.
The bear case
Skeptics will point to the beta of 0.8, indicating the stock is less volatile than the market but also that upside may be muted if macro-economic headwinds hit the insurance and banking sectors. A P/E of 21.9 is already modest, but the PEG of 1.03 hints that any slowdown below the 13.4% revenue growth could push the multiple into double-digit territory, eroding the price. The weakest pillar—Value at 77—means the market perceives the stock as overpriced relative to its cash-flow generation. A misstep in the AI rollout, or a slower-than-expected adoption in the Healthcare segment, could trigger a re-rating that pushes the price toward the week 52 low of $24.85. The “Buying back stock” signal is only helpful if the buyback is sizable enough to offset dilution from any future acquisitions.
What would change our mind
First, a quarterly free-cash-flow figure rising to $350m would lift the Value pillar and validate the reverse-DCF assumptions. Second, if the revenue growth metric accelerates beyond 13.4% YoY, the growth pillar would become even more compelling, forcing the market to reprice the stock nearer the week 52 high of $45.08. Finally, a significant increase in share repurchase activity—evidenced by a buyback that reduces shares outstanding by at least 5%—would directly address the Value weakness and could push the quality-growth score above the 85-mark threshold, turning the current undervaluation into a clear arbitrage. Until those triggers materialize, the stock remains a high-quality growth play priced conservatively relative to its earnings and cash-flow potential.